Antimicrobial strategy for severe community-acquired legionnaires' disease: a multicentre retrospective observational study. (13th February 2017)

• Record Type: Journal Article
• Authors: Cecchini, Jérôme; Tuffet, Samuel; Sonneville, Romain; Fartoukh, Muriel; Mayaux, Julien; Roux, Damien; Kouatchet, Achille; Boissier, Florence; Tchir, Martial; Thyrault, Martial; Maury, Eric; Jochmans, Sebastien; Mekontso Dessap, Armand; Brun-Buisson, Christian; de Prost, Nicolas
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 72:Number 5(2017:May)
• Page Start: 1502
• Page End: 1509
• Publication Date: 2017-02-13
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkx007
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract : Background: Legionnaires' disease (LD) is an important cause of community-acquired pneumonia with high mortality rates in the most severe cases. Objectives: To evaluate the effect of antimicrobial strategy on ICU mortality. Methods: Retrospective, observational study including patients admitted to 10 ICUs for severe community-acquired LD over a 10 year period (2005–15) and receiving an active therapy within 48 h of admission . Patients were stratified according to the antibiotic strategy administered: (i) fluoroquinolone-based versus non-fluoroquinolone-based therapy; and (ii) monotherapy versus combination therapy. The primary endpoint was in-ICU mortality. A multivariable Cox model and propensity score analyses were used. Results: Two hundred and eleven patients with severe LD were included. A fluoroquinolone-based and a combination therapy were administered to 159 (75%) and 123 (58%) patients, respectively. One hundred and forty-six patients (69%) developed acute respiratory distress syndrome and 54 (26%) died in the ICU. In-ICU mortality was lower in the fluoroquinolone-based than in the non-fluoroquinolone-based group (21% versus 39%, P = 0.01), and in the combination therapy than in the monotherapy group (20% versus 34%, P = 0.02). In multivariable analysis, a fluoroquinolone-based therapy, but not a combination therapy, was associated with a reduced risk of mortality [HR = 0.41, 95% CI 0.19–0.89; P = 0.02]. Conclusions: Patients with severe LD receiving a fluoroquinolone-based antimicrobial regimen in the early course of management had a lower in-ICU mortality, which persisted after adjusting for significant covariates.